We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

High-Sensitivity Troponin I Explored Post-Cardiac Surgery

By LabMedica International staff writers
Posted on 07 Mar 2022
Print article
Image: The Architect STAT Troponin-I assay is a 2-step chemiluminescent microparticle immunoassay designed to detect cardiac troponin I (cTnI) in serum and plasma using the ARCHITECT i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics)
Image: The Architect STAT Troponin-I assay is a 2-step chemiluminescent microparticle immunoassay designed to detect cardiac troponin I (cTnI) in serum and plasma using the ARCHITECT i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics)

Consensus recommendations regarding the threshold levels of cardiac troponin elevations for the definition of perioperative myocardial infarction and clinically important periprocedural myocardial injury in patients undergoing cardiac surgery range widely.

Although cardiac surgery has the potential to improve the quality and prolong the duration of a patient’s life, it is associated with complications. Prognostically important myocardial injury, detected by an elevated concentration of either cardiac troponin or creatine kinase MB4, is one of the most common complications after cardiac surgery and is associated with increased mortality.

A large international team of clinical scientists led by those from McMaster University (Hamilton, ON, USA) recruited patients from a convenience sample of 24 hospitals in 12 countries from May 2013 through April 2019. Patients were enrolled from North America (35.9%), Asia (28.3%), Europe (26.2%), South America (6.3%), and Australia (3.3%). The mean age of the study cohort was 63.3 years, 70.9% of the patients were men, 29.3% had a history of myocardial infarction, and 70.2% were White. Blood samples were obtained for measurement of cardiac troponin I levels with the ARCHITECT STAT assay (Abbott Laboratories, Abbott Park, IL, USA), (upper reference limit, 26 ng/L; limit of detection, 1 to 2 ng/L liter) before surgery, 3 to 12 hours after surgery, and on days 1, 2, and 3 after surgery.

The team reported that within the first day after surgery, troponin was measured in 13,662 patients. Among these patients, 13,316 patients (97.5%) had a peak troponin measurement of more than 260 ng/L (>10 times the upper reference limit), 12,217 patients (89.4%) had a peak troponin measurement of at least 910/L (≥35 times the upper reference limit), and 10,205 patients (74.7%) had a peak troponin measurement of at least 1,820 ng/L (≥70 times the upper reference limit). By 30 days after surgery, 296 patients (2.1%) had died and 399 patients (2.9%) had had a major vascular complication. Among patients who underwent other cardiac surgery, the corresponding threshold troponin level was 12,981 ng/L (95% CI, 2673 to 16,591), a level 499 times the upper reference limit.

The authors concluded that the levels of high-sensitivity troponin I after cardiac surgery that were associated with an increased risk of death within 30 days were substantially higher than levels currently recommended to define clinically important periprocedural myocardial injury. The study was published on March 3, 2022 in the journal The New England Journal of Medicine.

Related Links:
McMaster University 
Abbott Laboratories 

 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more